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Background: Benzodiazepines can improve sleep quality, but are also thought to cause
respiratory depression in patients with chronic obstructive pulmonary disease (COPD).
The aims of this study were to assess the effects of temazepam on indices of circadian
respiratory function, dyspnea, sleep quality, and sleepiness in patients with severe COPD
and insomnia.
Methods: In a double-blind, randomized, placebo-controlled, cross-over study in 14 stable
patients with COPD (mean FEV1 0.99 0.3 L) with insomnia, polysomnography with contin-
uous transcutaneous capnography and oximetry, arterial gas sampling, hypercapnic ventila-
tory response, multiple sleep latency test, Epworth Sleepiness Scale, dyspnea and sleep
visual analogue scales (VAS) were performed at baseline, after one week of temazepam
10 mg at bedtime and after one week of placebo.
Results: Temazepam did not cause statistically significant changes in mean transcutaneous
carbon dioxide tension during sleep compared to placebo (5.9 1.0 kPa vs. 6.3 1.4 kPa,gas; AHI, apneaehypopnea-index; COPD, chronic obstructive pulmonary disease; DI, desaturation
response; HR, heart rate; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial
partial pressure of carbon dioxide; PtcCO2, transcutaneous partial pressure of carbon dioxide; PSG,
vements; SaO2, arterial saturation of oxygen; SpO2, functional saturation of oxygen; TST, total sleep
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Temazepam and severe COPD 519p-value 0.27), nor in mean oxygen saturation (92 3% vs. 92 2%, p-value 0.31), nor in any
of the other investigated variables, except for the total sleep time and sleep latency VAS,
which improved with temazepam.
Conclusions: One week usage of temazepam 10 mg does not influence circadian respiratory
function, dyspnea, and sleepiness in patients with stable, severe, normocapnic COPD and
insomnia and it improves total sleep time and subjective sleep latency. However, this is
a preliminary explorative study for assessing the feasibility to perform a larger study on this
topic. The clinical implications of this study are very limited.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
The sleep of patients with chronic obstructive pulmonary
disease (COPD) is often of poor quality.1e5 Up to fifty-three
percent of these patients report sleep-related complaints2
characterized by a longer sleep latency, more frequent
arousals and awakenings, and more daytime sleepiness than
healthy individuals.
Sleep disturbances can substantially reduce patients’
quality of life6 and, as a result, patients often consult their
physician for hypnotics. Twenty-eight percent report
frequent use of hypnotics compared to 10% in age-matched
controls.4 Polysomnographic recordings show reductions in
total sleep time (TST) and duration of slow wave and rapid
eye movement (REM) sleep, more sleep state changes, and
an increase in number and severity of arousals during
sleep.5 Benzodiazepines are proven to influence sleep
quality beneficially7 and are the first-choice hypnotics
nowadays.8,9
However, ATS/ERS-guidelines10 state that hypnotics
should be avoided in patients with severe COPD. Benzodi-
azepines may negatively affect breathing during sleep in
these patients in several ways11e14; they may decrease the
central sensitivity to hypoxic and hypercapnic stimuli,11
they decrease the arousal response following hypoxaemia
or hypercapnia,12 and they increase upper airway resis-
tance, mainly due to myorelaxation.13 Other studies, by
contrast, did not show any adverse effects of benzodiaze-
pines in patients with COPD.15e18
Several problems occur when interpreting and
comparing these studies due to methodological flaws like
a single night of drug usage (a possible carry-over effect
may be overlooked), inclusion of subjects with varying
severity of COPD, the use of different benzodiazepines, and
the use of different respiratory outcome variables.
Furthermore, none of these studies were performed in
COPD patients with insomnia, precisely the patients one
might prescribe a hypnotic to. So although several studies
have been published about both the benefits and the risks
of the use of benzodiazepines in patients with COPD, their
use still remains controversial. The effects of temazepam
on breathing have, to our knowledge, not been studied in
patients with COPD.
The primary objective of this study was therefore to
examine whether prolonged usage of the benzodiazepine
temazepam influences indices of breathing and gas
exchange during sleep in patients with severe COPD who
experience insomnia. Secondary objectives were to
assess the effects of prolonged usage of temazepam ondiurnal breathing, gas exchange, and dyspnea in patients
with severe COPD and insomnia. In addition, sleep
quality and diurnal sleepiness were examined in these
patients.Methods and materials
Subjects
Subjects were recruited at the outpatient centre of the
Respiratory Medicine Department of the Rijnstate
Hospital, Arnhem, the Netherlands. Patients were eligible
for inclusion if they had COPD GOLD stage 3 or 419 without
an exacerbation in the past 6 weeks, and if they experi-
enced insomnia. GOLD stages 3 or 4 were chosen because
these patients were anticipated to show the most
profound adverse effects when these would occur. Exclu-
sion criteria were the use of any medication influencing
sleep architecture within 4 weeks before inclusion,
a history of alcohol, benzodiazepine or other drug
dependence, allergy to a benzodiazepine, a clinically
relevant sleep apnea syndrome (defined as having
a apneaehypopnea-index (AHI) 15, either measured
before enrolment or at the baseline polysomnography
(PSG)), and dependency on long-term oxygen therapy.
Written and oral informed consent was obtained from all
participants and the study was approved by our Institu-
tional Review Board.
Study design
All subjects were studied for three weeks in a double-blind,
randomized, cross-over design. Subjects were randomized
after the baseline measurements to use 10 mg temazepam
or placebo once a day orally, both during one week, sepa-
rated by a washout-period of one week. Randomization was
done by the hospital pharmacy. Subjects were instructed to
take the study medication 30 min before they went to bed.
Temazepam was proven to improve sleep quality
previously.20
The rationale for selecting the benzodiazepine temaze-
pam was based on its efficacy,20 its frequent use as
a hypnotic and Dutch guidelines,21 which advise the use of
temazepam 10 mg (or nitrazepam) as first choice hypnotic
due to its intermediate half-life and minimal daytime side
effects.8,9 The temazepam and placebo were provided by
the hospital pharmacy as a solution, which was produced as
previously described.22
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Before enrolment, all subjects underwent pulmonary
function testing with reversibility (after 400 mg salbuta-
mol). A baseline polysomnography (PSG) and a multiple
sleep latency test (MSLT) were done for acclimatization
purposes and to screen for any possible sleeping disorders.
At days 7 and 21 all subjects participated in the following
measurements: an arterial blood gas (ABG) was taken at
rest, the ventilatory response to hypercapnia (HCVR) was
measured, in normoxic conditions, by the steady state
method,23 an MSLT24 consisting of 4 naps at 2-h intervals
was performed, subjective dyspnea, sleepiness, sleep
latency and sleep quality in the past week were assessed
with 10-point visual analogue scales (VAS) and the Epworth
Sleepiness Scale (ESS) was used to evaluate subjective
sleepiness after temazepam and placebo use.25 Higher ESS
scores indicate a greater sleepiness, and a cut-off point of
10 is often used to distinguish between normal (<10) and
excessive (10) daytime sleepiness.25
To assess sleep quality with temazepam and placebo,
a PSG was performed at night 7 and night 21, which
included continuous electro-oculography (EOG), submental
muscle electromyography (EMG) and electro-encephalog-
raphy (EEG) (Sleepscreen, Viasys Healthcare, Hoechberg,
Germany). Together with the PSG, heart rate and rhythm
were measured by a continuous electrocardiography and
oxygen saturation (SpO2) and transcutaneous carbon
dioxide (PtcCO2) were continuously measured (TOSCA 500,
Linde Medical Sensors, Basel, Switzerland) to assess gas
exchange during sleep. Furthermore, airflow- and respira-
tory effort were measured with a nasal/oral thermistor and
thoracic and abdominal piezoelectric belts. A bilateral
anterior tibialis EMG was performed to exclude periodic leg
movements.
Definitions
An apnea was defined as a cessation of oronasal airflow
lasting 10 s, a hypopnea was defined as a decrease in
airflow and/or chest wall movement of 50% or more
occurring simultaneously with an oxygen desaturation, the
AHI was defined as the number of apneas and hypopneas
per hour sleep, an oxygen desaturation was defined as
a reduction in oxygen saturation of 4% from baseline and
the desaturation index (DI) was defined as the number of
desaturations per hour sleep. Parameters to describe sleep
quality were the total sleep time (TST), sleep-onset latency
(SOL), sleep efficiency (SE), the number of awakenings
(NAWK), and the amount of REM and non-REM (nREM) sleep.
Analysis
We aimed to detect a 0.5 kPa difference in PtcCO2 (based
on previous studies)26,27 at the 5% significance level for
a one-sided test with 80% power. With a crossover design,
this would require 14 patients. To anticipate possible
dropouts, we planned to include 17 patients.
The primary outcome parameters were the PtcCO2 and
SpO2 levels during sleep, and secondary parameters were
the AHI and DI, the HCVR, the ABG values, the levels ofsubjective and objective sleepiness (represented by VAS-
scales, ESS and MSLT outcomes), dyspnea sensation (VAS),
sleep latency (VAS), sleep quality (VAS), and the sleep
quality as measured by PSG. Both the slope (Dminute
ventilation (VE)/end-tidal carbon dioxide tension (PetCO2))
and intercept (L/min) of the HCVR were analyzed. Sleep
was manually staged according to standard methods28 by
two qualified sleep technicians blinded to the subject’s
treatment status.
Data are expressed as means (SD) for quantitative vari-
ables or as means SEM when percentages are compared.
We used a Student’s t test for paired series and c2 e test for
continuous and discrete variables respectively to compare
between the data obtained after a week temazepam and
the data obtained after a week placebo. P values <0.05
were considered statistically significant. All statistical
analyses were carried out using the SPSS version 12.0
statistical package (SPSS, Inc., Chicago, IL).
Results
Subjects
Fig. 1 shows a flow diagram of the selection of the subjects.
Seventeen patients were enrolled in the study, but 3
subsequently dropped out. One subject appeared from the
first PSG to have an obstructive sleep apneaehypopnea
syndrome and was therefore excluded; another subject
developed an exacerbation of his COPD during the study
and was excluded, and a third subject withdrew from
participation due to the burden of the measurements.
Fourteen subjects completed the study-protocol; their
demographic data and characteristics are presented in
Table 1. The sleep-related complaints of the subjects were
difficulty maintaining sleep (experienced by 8 subjects),
a prolonged sleep-onset latency (experienced by 7
subjects), extensive daytime sleepiness (experienced by
6 subjects), and nocturnal dyspnea (experienced by 2
subjects).
Respiratory and sleep variables
The effects of temazepam and placebo on diurnal and
nocturnal respiratory variables are listed in Table 2; their
effects on variables concerning sleep architecture and
sleep quality are listed in Table 3 and their effects on
daytime sleepiness are listed in Table 4. None of the
changes were statistically significant, except for the TST
(increased), the amount of stage 2 sleep (increased), and
the VAS-scale on sleep latency (improved).
Discussion
The main finding of the present study is that prolonged
usage of temazepam 10 mg in the evening did not influence
indices of gas exchange and breathing during sleep in our
patients with severe normocapnic COPD who experience
insomnia. Furthermore, it seems that diurnal gas exchange,
respiratory centre control, subjective dyspnea, objective
and subjective daytime sleepiness were not affected by
Figure 1 Flow diagram of selection of patients.
Temazepam and severe COPD 521temazepam compared to placebo, while TST and subjective
sleep latency improved in these patients.
Neither the indices of gas exchange during sleep (PtcCO2
and SpO2), nor the indices of breathing during sleep (AHITable 1 Characteristics of the 14 subjects enrolled in the
study.a
Patient data Values
Age, yr 61.6 8.0
Sex (M/F) 10/4
FEV1, L 0.99 0.3
FEV1, % predicted 33.5 9.2
FEV1/FVC (%) 32.7 13
Reversibility of FEV1, % predicted 3.34 3.6
BMI, kg/m2 23.2 5
Baseline PaCO2, kPa 5.4 0.4
Baseline PaO2, kPa 9.6 0.7
Smoking status, pack-years 43.1 15.9
Former, n 10 (71)
Current, n 4 (29)
Medication, N (%)
Inhaled corticosteroids 14 (100)
Anticholinergics 13 (93)
b2 agonists 9 (64)
Oral steroids 4 (29)
Theophylline 3 (21)
Proton pump inhibitors 4 (29)
Anticoagulants 4 (29)
Acetylcysteı¨ne 1 (7)
Diuretics 3 (21)
Other antihypertensiva 4 (29)
BMIZ Body Mass Index; FEV1Z Forced Expiratory Volume in 1 s;
FVCZ Forced Vital Capacity; PaCO2Z Arterial pressure of
carbon dioxide; PaO2Z Arterial pressure of oxygen.
a Data are expressed as mean SD or N. (%), unless otherwise
stated.and DI) were affected by temazepam compared to placebo.
Evidence that diurnal gas exchange, respiratory centre
control, and subjective dyspnea are not affected by
temazepam is that daytime PaCO2, PaO2, HCVR, and VAS
scales remained unchanged with temazepam.
Our findings are consistent with those of prior reports,15e18
but contrary to those found in other studies.11,14 These
studies were all randomized clinical trials with a sample size
ranging from 9 to 24 subjects. One study11 had a study pop-
ulation of healthy subjects, the other five only included
patients with COPD (FEV1 predicted ranging from 17 to 76%).
The study drugs were diazepam,11,18 flunitrazepam,14,15
nitrazepam,15 triazolam,14,17 zolpidem,14,16 and zopiclone.11
The adverse outcomes encountered were a reduction of the
hypercapnic ventilatory response caused by diazepam,11 and
increases in PaCO2 and decreases in minute ventilation
caused by flunitrazepam and triazolam.14
The differences in outcomes might be explained by one
of the following reasons. First, outcomes are likely to be
influenced by the pharmacological profiles of the used
benzodiazepines. This is, to our knowledge, the first study
to evaluate temazepam in the present context. Compari-
sons to other studies should therefore be done with care.
The intermediate half-life of temazepam may play a role in
the absence of diurnal effects, but this can only be seen as
an advantage of the drug.
Second, our outcomes might have been different when
a higher dose of temazepam would have been used.
Although larger doses (15e20 mg temazepam) are some-
times prescribed for insomnia, we chose to use the smallest
dose likely to be effective. Further studies are needed to
assess the adverse effects of larger doses.
Third, the designs of studies and duration of drug use (a
single night vs. one week) might play a role in outcomes.
With the prolonged use as was done in this study, a possible
carry-over effect could be examined. Fourth, it might be
that our study was too under-powered to demonstrate an
Table 2 Respiratory variables.a
Variables Baseline Temazepam Placebo p Valueb
PtcCO2 during sleep, kPa
Mean 6.2 0.6 5.9 1.0 6.3 1.4 0.27
Highest 6.9 0.6 6.4 1.1 7.3 2.0 0.13
Lowest 5.3 0.7 4.9 1.2 5.5 1.0 0.08
% TST with PtcCO2> 7 kPa 9.9 22.1 7.8 26.5 8.0 26.5 0.75
SaO2 during sleep, %
Mean 92 2 92 3 92 2 0.31
Lowest 82 5 81 4 83 5 0.24
% TST with SaO2< 90% 8.3 19.3 7.2 11.0 6.1 16.4 0.96
AHI, /h TST 5.4 5.9 6.8 6.3 5.1 5.2 0.40
DI, /h sleep 10.1 8.8 8.9 8.6 7.9 6.3 0.61
HCVR
Slope (L/min/kPa) 4.0 4.4 5.6 4.5 5.7 4.8 0.99
Intercept (L/min) 6.7 23.4 13.7 20.7 13.4 21.5 0.96
Daytime PaCO2, kPa 5.4 0.4 5.5 0.6 5.5 0.5 0.62
Daytime PaO2, kPa 9.6 0.7 9.3 1.0 9.6 0.9 0.14
Subjective dyspnea (VAS), pts 3.8 2.6 4.2 2.9 4.1 2.5 0.90
AHIZ Apneaehypopnea-index; DIZ Desaturation index; HCVRZ Ventilatory response to hypercapnia; PtcCO2Z Transcutaneous partial
pressure of carbon dioxide; SaO2ZOxygen saturation; TSTZ Total sleep time; VASZ Visual analogue scale.
Note that normal values of HCVR in healthy subjects are as follows: slope 13.9 7.1 L/min/kPa, intercept 62.9 36.8 L/min.34
a Data are expressed as mean SD.
b For comparisons between temazepam and placebo.
522 G. Stege et al.effect. This might especially concern any secondary vari-
ables, since the present sample size was based on the
primary variables PtcCO2 and SpO2. Outcomes in secondary
variables might have been different with a larger sample
size. Due to the crossover design, this study was capable to
detect a 0.5 kPa difference in PtcCO2 and a 4% difference in
nocturnal SpO2, both with 80% power, with only 14 subjects.
Temazepam beneficially influenced the sleep quality by
lengthening the TST, it improved the subjective sleep
latency, and increased the amount of stage 2 nREM sleep. ItTable 3 Sleep quality and architecture variables.a
Variables Baseline
TST, h 5.7 1.2
SE, % 81.0 10.7
SOL, min 43.2 38.7
NWAK, No./h TST 6.0 3.2
REM sleep latency, min 137.9 82.6
nREM 1, % of TST, minutes 27.0 13.4
98.1 57.2
nREM 2, % of TST, minutes 37.5 11.8
130.8 54.5
SWS, % of TST, minutes 21.0 10.3
68.8 28.7
REM, % of TST, minutes 14.4 6.9
48.3 22.6
nREM/REM, % 18 9
Sleep latency (VAS), pts 4.4 3.2
Sleep quality (VAS), pts 4.3 3.0
nREMZ Non-rapid eye movement sleep; NWAKZ Number of awaken
SOLZ Sleep-onset latency; SWSZ Slow wave sleep (i.e. sleep stage
scale.
a Data are expressed as mean SD.
b For comparisons between temazepam and placebo.did not significantly influence other parameters of sleep
quality and sleep architecture nor did it improve objective
and subjective daytime sleepiness in our population.
A strong point of this study is the measurement of
PtcCO2 during sleep. To our knowledge, this is one of the
first studies where PtcCO2 was measured to assess the
effects of a benzodiazepine on gas exchange during sleep.
Nocturnal measurements of PtcCO2 have rarely been per-
formed due to the insufficient accuracy and risk of burns
associated with older capnometers. The currentTemazepam Placebo p Valueb
6.3 1.0 5.4 1.1 0.03
86.3 10.1 80.8 14.1 0.19
21.1 20.8 21.6 11.7 0.94
6.3 4.3 5.4 1.8 0.49
114.1 58.9 142.4 74.3 0.22
21.8 8.8 25.1 13.9 0.45
88.4 37.7 75.1 45.8 0.38
45.6 7.7 42.9 11.1 0.50
168.8 34.4 140.0 44.6 0.03
19.4 7.9 19.3 7.6 0.93
74.9 35.8 61.1 23.0 0.10
13.2 8.0 12.8 7.0 0.84
51.0 32.3 49.7 42.7 0.93
16 11 15 10 0.76
3.3 2.8 4.6 3.2 0.03
3.4 3.0 4.3 3.6 0.11
ings; REMZ Rapid eye movement sleep; SEZ Sleep efficiency;
s nREM 3 and 4); TSTZ Total sleep time; VASZ Visual analogue
Co
Table 4 Variables on objective and subjective diurnal
sleepiness.a
Variables Baseline Temazepam Placebo p Valueb
MSLT, min. 16.5 4.6 15.8 4.6 14.7 4.6 0.38
ESS, pts. 6 4 5 4 6 4 0.13
Daytime
sleepiness
(VAS), pts
4.7 3.0 4.7 3.2 4.8 2.6 0.86
ESSZ Epworth Sleepiness Scale; MSLTZMultiple sleep latency
test; VASZ Visual Analogue Scale.
a Data are expressed as means SD.
b For comparisons between temazepam and placebo.
Temazepam and severe COPD 523transcutaneous device, by contrast, has been reported to
accurately assess PCO2 in routine respiratory practice,
29 in
critically ill adults,30 in newborns,31 and during cardiopul-
monary exercise testing32 without the occurrence of any
major complications. Although this apparatus has not yet
been validated during sleep, we think that it can accurately
measure nocturnal PtcCO2 since its use on an intensive care
unit is also for an extended period of time.
Other strong points are the inclusion of subjects with
only severe COPD (FEV1 predicted <50%), who in addition
experienced insomnia, the study period of 7 days instead of
a single day or night, and the timing of the measurements;
unlike several previous studies, we not only examined the
subjects awake, but also while they were asleep.
Limitations of this study are present as well. We did not
compare temazepam to other benzodiazepines or a non-
benzodiazepine benzodiazepine-receptor agonist (NBBRA).
An intermediate-acting benzodiazepine was chosen since
long- and short-acting benzodiazepines are not recom-
mended for the short-term management of insomnia, and
because only minor differences in efficacy exist between
NBBRA’s and benzodiazepines,33 these two groups of
hypnotics were not compared with each other.
Another limitation is the relatively low dosage of
temazepam, used for reasons mentioned above. Further-
more, at the start of the second study week the stability of
the COPD was not objectively confirmed with spirometry,
but only assessed on clinical grounds.
Temazepam caused no adverse respiratory events for
the group as a whole, but it is possible that these events
occur on a individual scale, because some individuals,
like patients with other, unfavorable pharmacodynamics,
patients who may take extra doses of temazepam, or
patients with other sleep disturbances, might be more
susceptible to adverse events than others. Therefore, the
sample size may have been too small to include some of
those ‘more susceptible’ patients. Studies with larger
sample sizes will be needed to include some of those more
susceptible patients as well.
Our conclusions cannot safely be applied to other, related
situations such as the use of other benzodiazepines, larger
doses of temazepam, periods longer than our study period of
one week, or to patients with an exacerbation of their COPD,
to hypercapnic COPD patients, to patients with COPD plus
a sleep-apnea syndrome or to patients with other pulmonary
diseases. In the mentioned situations and patients groups,
use of temazepam is still to be seen as experimental.In the light of the mentioned limitations, this study is
best to be seen as a preliminary explorative study for
assessing the feasibility to perform a larger study on this
topic, and the clinical implications of this study are very
limited. Larger studies would be necessary to determine
the role of benzodiazepines and NBBRA’s in the pharma-
cological management of insomnia during an exacerbation
in patients with (severe) COPD and in the aforementioned
situations and patients groups. Until those studies are
performed, guidelines on this subject like the ATSeERS
guideline10 should not be more liberate and temazepam
and other benzodiazepines should still be used with great
caution in these situations and patients. Also, temazepam
should only be used in patients with COPD when other,
non-pharmacological therapies for insomnia have failed,
and then only for a short period. Its use should carefully
be watched and reevaluated when the patient develops
an exacerbation of the COPD or worsens for other
reasons.
Physicians should be aware that the prevalence of
insomnia in patients with COPD can be as high as 50%,2 and
that insomnia can have a major negative impact on the
quality of life of these patients. Hence, by improving
sleep quality physicians have a tool to presumably improve
the quality of life of their patients with COPD.
In conclusion, in this preliminary study repeated doses of
temazepam did not adversely affect nocturnal respiratory
function in our severe but stable normocapnic COPD
patients without complications, but it did improve TST and
sleep-onset latency. Furthermore, temazepam did not
affect diurnal gas exchange, diurnal central respiratory
centers, and subjective dyspnea.
Temazepam can, in our view, not automatically be dis-
missed from patients with stable, normocapnic COPD who
experience insomnia and consequently have a reduced
quality of life, but it remains to be seen as a last resort
when other, non-pharmacological remedies have failed.
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